A Randomized, 12-month, placebo-controlled, pivotal, cross-over study of migalastat in treatment naïve Fabry patients who have an amenable mutation and GI symptoms.

Trial Profile

A Randomized, 12-month, placebo-controlled, pivotal, cross-over study of migalastat in treatment naïve Fabry patients who have an amenable mutation and GI symptoms.

Planning
Phase of Trial: Phase III

Latest Information Update: 11 Jul 2017

At a glance

  • Drugs Migalastat (Primary)
  • Indications Fabry's disease
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 11 Jul 2017 According to an Amicus Therapeutics media release, this additional Phase 3 study previously requested by the Agency to assess Gastrointestinal (GI) symptoms is no longer required prior to an NDA submission.
    • 06 Dec 2016 New trial record
    • 28 Nov 2016 According to an Amicus Therapeutics media release, company is working with FDA to finalize the protocol of this trial and plans to initiate enrollment in 2017, with data expected in 2019. This trial will generate additional data which will support regulatory approval of migalastat for Fabry disease in the USA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top